Added text to state that a phase II feasibility study used chemotherapy induction with methotrexate, temozolomide, and rituximab plus consolidation with etoposide and high-dose cytarabine; with a median follow-up of 4.9 years, this phase II Cancer and Leukemia Group B (CALGB) trial of 44 patients reported a complete radiographic response in 66% of the patients, a 2-year progression-free survival of 57%, and an estimated overall survival of 65% at 4 years (cited Rubenstein et al. as reference 34 and level of evidence 3iiiDiv). Also added that a randomized, prospective trial by the CALGB will compare this nonstandard induction regimen versus the same induction chemotherapy with myeloablative peripheral stem cell transplantation.
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
In this article
This information is produced and provided by the National
Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National
Institute via the Internet web site at http://
.gov or call 1-800-4-CANCER.
WebMD Public Information from the National Cancer Institute
This information is not intended to replace the advice of a doctor.
Healthwise disclaims any liability for the decisions you make based on this